Chronic Kidney Disease (Stage 1-2)
Conditions
Interventions
Treatment group:Administer the modified Qilong Fángfeng Decoction with adjunctive therapy. The herbal prescription is to be taken once daily, divided into two warm administrations. The herbal composit
Control Group:Administer valsartan capsules along with basic therapy. Valsartan capsules, 80 mg per dose, once daily orally.
Sponsors
Tangshan Workers' Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with primary chronic glomerular disease, meeting the criteria for chronic kidney disease (CKD stage 1-2). 2. Age between 18-70 years old. 3. Presents with mild to moderate proteinuria (24-hour urine protein quantification: 0.5-2.5g), with or without microscopic hematuria. 4.TCM syndrome differentiation conforms to Pi-Shen Qi deficiency combined with blood stasis. 5. Patients who have used ACEI/ARB prior to enrollment must undergo a 2-week washout period, or have not used ACEI/ARB prior to enrollment. 6. Non-dialysis patients with effective control of exacerbating factors such as infection, acidosis, electrolyte imbalance, and hypertension, with stable condition. Blood pressure is within 130-90/80-60 mmHg, and serum potassium is within the normal range. 7. Voluntarily agrees to participate in this study and has signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Proteinuria caused by secondary factors, such as lupus nephritis, diabetic nephropathy, etc. 2. Severe proteinuria (24-hour urine protein quantification of 2.5g or more) and nephrotic syndrome. 3. Those who have used glucocorticoids, immunosuppressive agents, or Tripterygium formulations within the past three months. 4. Patients with mental illness, infectious diseases, or pregnancy. 5. Those with chronic liver disease, myocardial fibrosis, and pulmonary interstitial fibrosis, etc. 6. Patients with acute kidney failure, or those who have undergone kidney transplantation. 7. Patients with severe uncontrolled infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinalysis;24-hour urinary protein quantification; | — |
Countries
China
Contacts
Public ContactLi Shuang
Tangshan Workers' Hospital
Outcome results
None listed